| Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma AL Garfall, EA Stadtmauer, WT Hwang, SF Lacey, JJ Melenhorst, ... JCI insight 3 (8), 2018 | 217 | 2018 |
| Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic AC Rosen, EC Case, SW Dusza, Y Balagula, J Gordon, DP West, ... American journal of clinical dermatology 14, 327-333, 2013 | 175 | 2013 |
| Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions VM Orellana-Noia, DR Reed, AA McCook, JM Sen, CM Barlow, ... Blood, The Journal of the American Society of Hematology 139 (3), 413-423, 2022 | 87 | 2022 |
| Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics P Torka, SK Kothari, S Sundaram, S Li, LJ Medeiros, EC Ayers, ... Blood advances 4 (2), 253-262, 2020 | 38 | 2020 |
| Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure EC Ayers, S Li, LJ Medeiros, DA Bond, KJ Maddocks, P Torka, ... Cancer 126 (2), 293-303, 2020 | 37 | 2020 |
| Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy SM Bair, JD Brandstadter, EC Ayers, EA Stadtmauer Cancer 126 (9), 1837-1855, 2020 | 34 | 2020 |
| CNS prophylaxis during front-line therapy in aggressive non-Hodgkin lymphomas: real-world outcomes and practice patterns from 19 US academic institutions VM Orellana-Noia, DR Reed, JM Sen, C Barlow, MK Malecek, BS Kahl, ... Blood 136, 27-28, 2020 | 16 | 2020 |
| Real world outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma receiving palliative intent therapies EC Ayers, D Margolis, DJ Landsburg Clinical Lymphoma Myeloma and Leukemia 20 (10), 661-667, 2020 | 15 | 2020 |
| Poor outcomes for double‐hit lymphoma patients treated with curative‐intent second‐line immunochemotherapy following failure of intensive front‐line immunochemotherapy DJ Landsburg, EC Ayers, DA Bond, KJ Maddocks, R Karmali, A Behdad, ... British journal of haematology 189 (2), 313-317, 2020 | 13 | 2020 |
| High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study AS Zayac, DJ Landsburg, ME Hughes, AM Bock, GS Nowakowski, ... Blood advances, 2023 | 12 | 2023 |
| Richter's Transformation in the era of kinase inhibitor therapy: a review EC Ayers, AR Mato Clinical Lymphoma Myeloma and Leukemia 17 (1), 1-6, 2017 | 12 | 2017 |
| Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study BT Hess, A Giri, Y Park, KK Patel, BK Link, GS Nowakowski, SM Maliske, ... American journal of hematology 98 (2), 300-308, 2023 | 10 | 2023 |
| Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort JT Bowers, JL Anna, SM Bair, K Annunzio, N Epperla, J Joy Pullukkara, ... Blood Advances, bloodadvances. 2023010622, 2023 | 9 | 2023 |
| Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL … N Roberts, J Lister, NN Bennani, S Jain, T Battaglia, EC Ayers, CA Portell, ... Blood 140 (Supplement 1), 9425-9426, 2022 | 5 | 2022 |
| Personalized management approaches in lymphoma: Utility of fluorodeoxyglucose-PET imaging EC Ayers, S Fardin, S Gholami, A Alavi, AR Mato PET clinics 11 (3), 209-218, 2016 | 5 | 2016 |
| Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us? J Lantz, CA Portell, EC Ayers Blood Reviews, 101101, 2023 | 4 | 2023 |
| High-grade B-cell lymphoma, not otherwise specified (HGBL, NOS): characteristics, treatment, and outcomes from 17 academic US centers A Zayac, DJ Landsburg, M Hughes, EC Ayers, M Girton, M Hu, ... Blood 138 (Supplement 1), 455-455, 2021 | 4 | 2021 |
| Outcomes for double hit lymphoma patients identified via routine vs selective testing for MYC rearrangement ZAK Frosch, SD Nasta, SJ Schuster, J Svoboda, SK Barta, JN Gerson, ... Blood 134, 1607, 2019 | 4 | 2019 |
| Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status A Behdad, CS Boddy, AJ Fought, T Taxter, MK Falkiewicz, E Ayers, ... Leukemia & Lymphoma, 2019 | 4 | 2019 |
| Outcomes of patients with limited-stage aggressive large B-cell lymphoma with MYC rearrangement with and without BCL2 and/or BCL6 rearrangements: a retrospective analysis from … SK Kothari, S Li, LJ Medeiros, EC Ayers, DJ Landsburg, DA Bond, ... Blood 132, 451, 2018 | 3 | 2018 |
